Nutshell Asset Management Ltd Invests $1.30 Million in Johnson & Johnson (NYSE:JNJ)

Nutshell Asset Management Ltd bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 9,000 shares of the company’s stock, valued at approximately $1,302,000. Johnson & Johnson accounts for approximately 0.8% of Nutshell Asset Management Ltd’s holdings, making the stock its 26th largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. Oregon Pacific Wealth Management LLC bought a new stake in Johnson & Johnson in the fourth quarter worth about $949,000. Horan Securities Inc. grew its position in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after buying an additional 90 shares during the last quarter. Strategic Financial Concepts LLC increased its holdings in shares of Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after buying an additional 1,271 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $69,859,000. Finally, KPP Advisory Services LLC raised its position in shares of Johnson & Johnson by 4.7% during the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock worth $1,662,000 after purchasing an additional 515 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday. Finally, Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 4.3 %

Shares of JNJ opened at $153.03 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a market cap of $368.77 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a fifty day moving average price of $159.75 and a two-hundred day moving average price of $155.91.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.29 earnings per share. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.